March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
55 citations
,
October 1975 in “Circulation” Minoxidil, propranolol, and furosemide effectively control severe hypertension, but may cause sodium retention.
1 citations
,
June 2023 in “Frontiers in Pharmacology” Vasodilators may worsen abdominal aortic aneurysm.
44 citations
,
July 1990 in “Journal of the American College of Cardiology” Captopril reduces heart mass, while minoxidil has opposite effects and side effects.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
June 1982 in “Reactions (Auckland)” Metoprolol and propranolol may cause hair loss.
These medications for BPH have known risks and may have new side effects.
2 citations
,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
January 2019 in “Urology Practice” Urologists prescribe newer medications more often than primary care physicians, who could benefit from more education on treatment options.
April 2011 in “The FASEB Journal” Amlodipine impairs fertility in male rats by affecting sperm and testicular structure.
12 citations
,
April 2020 in “Medical hypotheses” Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.
4 citations
,
April 2020 in “medRxiv (Cold Spring Harbor Laboratory)” Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
1 citations
,
June 2016 in “Annals of the rheumatic diseases” Retinoids may help treat lupus nephritis and reduce steroid use.
1 citations
,
July 2022 in “Cancer Epidemiology, Biomarkers & Prevention” 5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
July 2025 in “Journal of Investigative Dermatology” Spironolactone can safely lower blood pressure in patients on other blood pressure medications, but may slightly increase the risk of low blood pressure.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
5 citations
,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
11 citations
,
January 1980 in “Southern Medical Journal” Minoxidil effectively treats severe hypertension but has notable side effects.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
March 2025 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil doesn't affect blood pressure in patients taking blood pressure meds.
49 citations
,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
102 citations
,
September 1977 in “The Lancet” Minoxidil with propranolol and diuretics lowers blood pressure but causes fluid retention and hair growth.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
December 2017 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
April 2022 in “Reactions Weekly”